CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications

[1]  Yuh Min Chook,et al.  Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia. , 2012, Blood.

[2]  N. Grishin,et al.  NESdb: a database of NES-containing CRM1 cargoes , 2012, Molecular biology of the cell.

[3]  Guido Marcucci,et al.  Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia. , 2012, Blood.

[4]  Michael A. Sellitto,et al.  Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. , 2012, Blood.

[5]  A T Look,et al.  Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells , 2012, Leukemia.

[6]  D. Sullivan,et al.  Nuclear export of proteins and drug resistance in cancer. , 2012, Biochemical pharmacology.

[7]  S. Mousses,et al.  Identification of molecular vulnerabilities in human multiple myeloma cells by RNA interference lethality screening of the druggable genome. , 2012, Cancer research.

[8]  M. Oren,et al.  Importin 7 and exportin 1 link c-Myc and p53 to regulation of ribosomal biogenesis. , 2012, Molecular cell.

[9]  B. Henderson,et al.  Characterization of BRCA1 Protein Targeting, Dynamics, and Function at the Centrosome , 2012, The Journal of Biological Chemistry.

[10]  Y. Pekarsky,et al.  NOTCH1 mutations in CLL associated with trisomy 12. , 2012, Blood.

[11]  Donald W Kufe,et al.  CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity. , 2011, Blood.

[12]  Juliane C. Dohm,et al.  Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia , 2011, Nature.

[13]  V. Leaner,et al.  The nuclear exporter, Crm1, is regulated by NFY and Sp1 in cancer cells and repressed by p53 in response to DNA damage. , 2011, Biochimica et biophysica acta.

[14]  P. Koty,et al.  p53-dependent anticancer effects of leptomycin B on lung adenocarcinoma , 2011, Cancer Chemotherapy and Pharmacology.

[15]  P. Silver,et al.  Whole genome siRNA cell-based screen links mitochondria to Akt signaling network through uncoupling of electron transport chain , 2011, Molecular Biology of the Cell.

[16]  T. Marafioti,et al.  APRIL promotes cell-cycle progression in primary multiple myeloma cells: influence of D-type cyclin group and translocation status. , 2011, Blood.

[17]  K. Anderson,et al.  Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anti-cancer drug activity , 2010, Nature Medicine.

[18]  Li-wei Wang,et al.  Prognostic value of CRM1 in pancreas cancer. , 2009, Clinical and investigative medicine. Medecine clinique et experimentale.

[19]  Li-wei Wang,et al.  Prognostic value of CRM1in pancreas cancer , 2009 .

[20]  Peter Washausen,et al.  Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition. , 2009, Cancer research.

[21]  M. Birrer,et al.  The Karyopherin proteins, Crm1 and Karyopherin β1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation , 2009, International journal of cancer.

[22]  S. Mutka,et al.  Identification of nuclear export inhibitors with potent anticancer activity in vivo. , 2009, Cancer research.

[23]  D. Sullivan,et al.  CRM1-mediated nuclear export of proteins and drug resistance in cancer. , 2008, Current medicinal chemistry.

[24]  N. Munshi,et al.  Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. , 2008, Blood.

[25]  Carsten Denkert,et al.  Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer , 2008, Cancer.

[26]  S. Hanai,et al.  Inhibition of Crm1–p53 interaction and nuclear export of p53 by poly(ADP-ribosyl)ation , 2007, Nature Cell Biology.

[27]  N. Munshi,et al.  Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis. , 2007, Blood.

[28]  Kenneth C. Anderson,et al.  Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets , 2007, Nature Reviews Cancer.

[29]  J. Miguel,et al.  Gene expression profiling of B lymphocytes and plasma cells from Waldenström's macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals , 2007, Leukemia.

[30]  Anthony Boral,et al.  Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. , 2006, Blood.

[31]  Yongsheng Huang,et al.  A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. , 2006, Blood.

[32]  David R Williams,et al.  Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. , 2006, Blood.

[33]  John Crowley,et al.  The molecular classification of multiple myeloma. , 2006, Blood.

[34]  T. Mak,et al.  FOXO3a-dependent regulation of Puma in response to cytokine/growth factor withdrawal , 2006, The Journal of experimental medicine.

[35]  N. Munshi,et al.  Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. , 2006, Cancer research.

[36]  Y. Toyama,et al.  DC-STAMP is essential for cell–cell fusion in osteoclasts and foreign body giant cells , 2005, The Journal of experimental medicine.

[37]  Hao Jiang,et al.  Triple Layer Control: Phosphorylation, Acetylation and Ubiquitination of FOXO Proteins , 2005, Cell cycle.

[38]  S. Bicciato,et al.  Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma , 2005, Oncogene.

[39]  K. Toh,et al.  RANKL-induced DC-STAMP Is Essential for Osteoclastogenesis , 2004, The Journal of experimental medicine.

[40]  R. Jove,et al.  Human topoisomerase IIα nuclear export is mediated by two CRM-1-dependent nuclear export signals , 2004, Journal of Cell Science.

[41]  A. Grinberg,et al.  Visualization of Myc/Max/Mad Family Dimers and the Competition for Dimerization in Living Cells , 2004, Molecular and Cellular Biology.

[42]  K. Tarte,et al.  BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. , 2004, Blood.

[43]  J. Cleveland,et al.  Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. , 2003, Cancer cell.

[44]  Hiroshi Takayanagi,et al.  Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. , 2002, Developmental cell.

[45]  Minoru Yoshida,et al.  A nuclear export signal in the N-terminal regulatory domain of IκBα controls cytoplasmic localization of inactive NF-κB/IκBα complexes , 2000 .

[46]  E. Newlands,et al.  Phase I trial of elactocin. , 1996, British Journal of Cancer.

[47]  K. Sikora,et al.  Leukemia , 1984, British Journal of Cancer.

[48]  Y. Dong,et al.  The expression of CRM1 is associated with prognosis in human osteosarcoma. , 2009, Oncology reports.

[49]  N. Kudo,et al.  A nuclear export signal in the N-terminal regulatory domain of IkappaBalpha controls cytoplasmic localization of inactive NF-kappaB/IkappaBalpha complexes. , 2000, Proceedings of the National Academy of Sciences of the United States of America.